Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy.

Author(s): Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S, EPMN 105 Study Group

Affiliation(s): Department of Neurology, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA. michael.privitera@uc.edu

Publication date & source: 2003-03, Acta Neurol Scand., 107(3):165-75.

Publication type: Clinical Trial; Randomized Controlled Trial

OBJECTIVES: To compare topiramate (TPM) with investigator's choice of carbamazepine (CBZ) or valproate (VPA) for initial treatment in patients with newly diagnosed epilepsy. MATERIAL AND METHODS: In patients with epilepsy diagnosed within previous 3 months, investigators selected CBZ (600 mg/day) or VPA (1250 mg/day) as preferred therapy based on the patient's clinical presentation. Based on investigators' treatment choice, patients (n=613) were assigned to the CBZ or VPA treatment branch. Within each branch, patients were randomized to double-blind treatment with the traditional antiepileptic drugs (CBZ or VPA), TPM 100 mg/day, or TPM 200 mg/day. Patients continued double-blind treatment until exiting the study or until 6 months after last patient randomized. RESULTS: No statistically significant differences between fixed doses of TPM and CBZ or VPA were observed in efficacy measures: time to exit, time to first seizure, and the proportion of patients seizure-free during the last 6 months of treatment. TPM 100 mg/day was associated with the fewest discontinuations due to adverse events. CONCLUSION: In patients with newly diagnosed epilepsy, an initial target dose of TPM 100 mg/day is at least as effective as therapeutic doses of CBZ and VPA.